Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y.

Med Oncol. 2013;30(2):583. doi: 10.1007/s12032-013-0583-y. Epub 2013 Apr 23.

PMID:
23609192
2.

Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1117-27. doi: 10.1007/s00432-013-1422-4. Epub 2013 Apr 2.

PMID:
23546595
3.

Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.

PMID:
21837532
4.

Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.

Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.

Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.

5.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

6.

[Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer].

Sheng WW, Dong M, Zhou JP, Kong FM, Li YJ.

Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3407-11. Chinese.

PMID:
23327700
7.

Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus.

Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J.

Cancer Biol Ther. 2009 Aug;8(16):1527-33. Epub 2009 Aug 13.

PMID:
19571666
8.

Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions.

Funel N, Morelli M, Giovannetti E, Del Chiaro M, Pollina LE, Mosca F, Boggi U, Cavazzana A, Campani D.

Pancreatology. 2011;11(1):30-42. doi: 10.1159/000322990. Epub 2011 Mar 16.

PMID:
21412023
9.

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.

Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W.

BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.

10.

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K.

J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.

PMID:
19789838
11.

Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z.

Int J Oncol. 2011 Jan;38(1):133-43.

PMID:
21109934
12.

Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.

Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH.

Oncol Rep. 2014 Mar;31(3):1157-64. doi: 10.3892/or.2013.2960. Epub 2013 Dec 31.

PMID:
24398877
13.

Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.

Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, Friess H.

Int J Oncol. 2008 Aug;33(2):297-308.

PMID:
18636150
14.

Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.

Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I.

Cancer Res. 2013 Apr 1;73(7):2357-67. doi: 10.1158/0008-5472.CAN-12-3359. Epub 2013 Jan 31.

15.

Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.

Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.

Pancreas. 2008 Mar;36(2):160-7. doi: 10.1097/MPA.0b013e31815750f0.

PMID:
18376307
16.

Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Gaida MM, Bach ST, Günther F, Baseras B, Tschaharganeh DF, Welsch T, Felix K, Bergmann F, Hänsch GM, Wente MN.

Pathol Oncol Res. 2012 Apr;18(2):299-307. doi: 10.1007/s12253-011-9444-1. Epub 2011 Sep 12.

PMID:
21910036
17.

Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.

Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME.

J Mol Histol. 2009 Feb;40(1):23-9. doi: 10.1007/s10735-008-9209-7. Epub 2009 Jan 22.

PMID:
19160064
18.

Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.

Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB.

Pancreas. 2010 Mar;39(2):243-7. doi: 10.1097/MPA.0b013e3181bae8ab.

PMID:
19820423
19.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142. Epub 2011 Oct 7.

20.

Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma.

Mahawithitwong P, Ohuchida K, Ikenaga N, Fujita H, Zhao M, Kozono S, Shindo K, Ohtsuka T, Mizumoto K, Tanaka M.

Pancreas. 2013 May;42(4):663-9. doi: 10.1097/MPA.0b013e318279bd66.

PMID:
23508013

Supplemental Content

Support Center